Método Benozzi® Background

When I started studying ophthalmology in 1977, Belgium was the ultimate mecca, where the best minds gathered to discuss how to treat patients from all over the world.

Russia and the USA were working separately and the Belgian Professor Jules François would, among other things, work to unify their criteria.

In those years ophthalmologists didn’t think there could be a treatment for presbyopia that didn’t involve corrective eye wear. On the contrary, we were quite happy to get patients reading again, even with glasses.

However, curiously enough, we already had the drugs we needed to restore accommodation, though they were being used to treat other conditions.

In 1978, my first teacher at Durand Hospital, in Buenos Aires, Professor Gustavo Piantoni, helped me get a scholarship to work with Professor Jules François in Belgium.

From that moment on, I became his disciple, ophthalmologist, researcher and critic of medical activity in general, and of ophthalmology in particular.

The Beginning of
Método Benozzi®

With Professor Victoria, we worked hard and published a number of research studies. Among the different drugs we tested was the main component of this discovery to treat presbyopia without glasses or surgery.

In 1999, twenty two years later, I started to experience presbyopia limitations. It occurred to me that this drug I had been using to treat other conditions could restore my close up vision. To get rid of glasses I only had to find a way to restore accommodation without affecting distance vision.

That same year I achieved my goal and started treating myself, my colleagues and my friends with this combination of drugs ophthalmologists had already been using since the 60s to treat other conditions.


We had remarkable results: not only were we able to restore accommodation and do without glasses, but also stopped presbyopia from progressing in all of our patients, without exception.


After some adjusting and fine-tuning, in 2003 I decided to join the Spanish University Foundation to finance the eye drops and the American and European patents, to be able to manufacture the drug, registered under my name.

After Europe, USA and Japan.

In 2006, the European Patent Office accepted and published the European patent.

In 2013, The United States Patent and Trademark Office published the American patent.